Latest Outlook Therapeutics News & Updates

See the latest news and media coverage for Outlook Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Outlook Therapeutics

Late-stage biopharmaceutical company developing ophthalmic bevacizumab

outlooktherapeutics.com

Headquarters: Cranbury, United States
Founded year: 2011
Company type: Public company
Number of employees: 10–60

Last updated Today

Latest news about Outlook Therapeutics

Company announcements

Yesterday Outlook Therapeutics

Outlook Therapeutics prices $5.0 million registered direct offering

The offering to GMS Ventures at $0.5855 per share will close May 29, 2026, with proceeds for working capital.

May 26 Outlook Therapeutics

Outlook Therapeutics wins FDA appeal for ONS-5010

Company plans to resubmit BLA in June 2026 after FDA confirmed substantial evidence of effectiveness for nAMD.

April 22 Outlook Therapeutics

Outlook Therapeutics announces $5.0 million registered direct offering

The offering includes 16.1 million shares at $0.31 per share, with concurrent private placement of warrants.

April 21 Outlook Therapeutics

Outlook Therapeutics completes FDR meeting with FDA for ONS-5010

Formal decision expected in May 2026; meeting follows CRL for wet AMD treatment.

Media coverage

Yesterday Markets Insider

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases...

Yesterday MSN

OTLK stock rocket nearly 140%: FDA's Lytenava approval pushes stock on track for best week on record

The FDA on Tuesday granted approval to its eye disease drug Lytenava. ・The treatment has already been approved in the European Union and the United...

May 27 The Globe and Mail

Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug

Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.

May 26 The Globe and Mail

Outlook Therapeutics Wins FDA Appeal for LYTENAVA Resubmission

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Outlook Therapeutics ( (OTLK)) just unveiled an update. On May 26...

Never miss news about Outlook Therapeutics

Track Outlook Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Outlook Therapeutics competitors & trending companies

Browse news for competitors to Outlook Therapeutics and other trending companies.